Insulin pump halves risk of death from heart disease

Image
Press Trust of India London
Last Updated : Aug 12 2015 | 4:57 PM IST
People with type 1 diabetes who use insulin pump therapy have almost 50 per cent less risk of dying from cardiovascular disease than those who take insulin by multiple daily injections, a new Swedish study has found.
Researchers monitored 18,168 Swedes with type 1 diabetes from 2005 to 2012. While 2,441 of the subjects used insulin pump therapy, the others relied on multiple daily injections.
The study found that insulin pump users had a substantially lower risk of dying of cardiovascular disease than the daily injection group.
"We carefully analysed the findings to eliminate the risk of bias or confounding and concluded that the effect had been fully verified," said Isabelle Steineck, researcher at Sahlgrenska Academy in Sweden.
The next step will be to identify the mechanisms that explain the extra benefits of insulin pump therapy. Steineck believes that one reason for the difference between the two therapies is that the insulin pump method is accompanied by more extensive patient training and more frequent blood glucose monitoring.
"There is a rationale for insulin pump treatment resulting in more stable blood glucose concentrations than multiple daily injections," she said.
"Previous studies have shown that insulin pump can reduce the frequencies of severe hypoglycemic episodes. Severe hypoglycaemia can be a risk factor for cardiovascular events, particularly among high risk individuals," Steineck said.
"We evaluated the patients who used insulin pump therapy and do not know if the observed effect is attributable to continuous infusion of insulin or that some of the effect is attributable to intensified glucose monitoring, increased motivation to control blood glucose, or a better knowledge about having diabetes type 1," said Steineck.
The researchers have concluded that insulin pumps not only make life easier for patients, but represent a safe and effective treatment method.
The study was published in the British Medical Journal.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 12 2015 | 4:57 PM IST

Next Story